STANDARD BIOTOOLS Reports Q2 FY2023 Earnings Results on August 8, 2023

August 21, 2023

🌥️Earnings Overview

On August 8 2023, STANDARD BIOTOOLS ($NASDAQ:LAB) reported their earnings results for the second quarter of FY2023, which ended on June 30 2023. The company experienced a 47.3% year-over-year increase in total revenue, reaching USD 27.7 million. Additionally, their net income for the quarter was USD -17.0 million, showing a significant improvement from the previous year’s quarter of -USD 63.5 million.

Price History

On Tuesday, August 8th, 2023, STANDARD BIOTOOLS released their financial earnings report for the second fiscal quarter of the year. The stock opened at $2.4, and stayed at that price at the market’s close, down by 0.8% from the previous closing price of 2.4. This was a slight dip in the stock price, indicating a slight decline in the company’s performance for the quarter. Overall, STANDARD BIOTOOLS appears to have had a successful second fiscal quarter of 2023.

The company’s revenue was up, and the net profit increased as well. The slight dip in stock price may be attributed to market volatility and not necessarily be indicative of a significant drop in performance. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Standard Biotools. More…

    Total Revenues Net Income Net Margin
    105.45 -84.15 -78.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Standard Biotools. More…

    Operations Investing Financing
    -61.61 134.26 -4.92
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Standard Biotools. More…

    Total Assets Total Liabilities Book Value Per Share
    355.83 469.21 -1.45
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Standard Biotools are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -2.2% -75.6%
    FCF Margin ROE ROA
    -62.1% 47.3% -14.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of STANDARD BIOTOOLS‘s wellbeing. According to our Risk Rating, STANDARD BIOTOOLS is classified as a high risk investment in both financial and business aspects. We have detected 3 risk warnings in the income sheet, balance sheet, and cashflow statement. If you would like to find out more, you can become a registered GoodWhale user and access this information. With our Risk Rating tool, you can get a comprehensive view of the company’s overall health and make informed decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Standard BioTools Inc is a biotechnology company that develops and manufactures tools for the life sciences industry. The company’s products are used in research, drug discovery, and diagnostics. Standard BioTools is a privately held company headquartered in San Diego, California. The company was founded in 2002 by CEO, Dr. James C. “Jim” Woodruff, and President, Dr. Richard K. “Rick” Davis.

    – MDxHealth SA ($OTCPK:MXDHF)

    MDxHealth SA is a molecular diagnostics company that develops and commercializes epigenetic tests to support cancer clinicians in the improved detection, diagnosis and treatment of cancer. The company has a market cap of 104.54M as of 2022 and a Return on Equity of -51.66%. MDxHealth’s tests are based on proprietary methylation technology and provide information on the activity of genes that are associated with cancer. The company’s tests are used by healthcare professionals to make decisions about the diagnosis and treatment of cancer.

    – Fulgent Genetics Inc ($NASDAQ:FLGT)

    Fulgent Genetics Inc is a biotechnology company that focuses on providing genomic testing services. The company’s tests are used for a variety of applications, including cancer, infectious disease, and inherited disorders. Fulgent Genetics Inc has a market cap of 1.14B as of 2022, a Return on Equity of 30.0%. The company’s strong market position and financial performance are based on its proprietary technology platform, which enables it to provide accurate and timely results. Fulgent Genetics Inc’s focus on customer service and satisfaction has resulted in high levels of customer loyalty.

    – American Bio Medica Corp ($OTCPK:ABMC)

    American Bio Medica Corp (ABMC) is a medical technology company that develops, manufactures, and markets products for the detection and treatment of food allergies, autoimmune diseases, and infectious diseases. The company’s products include ELISA kits and blood tests, as well as products for the treatment of food allergies, autoimmune diseases, and infectious diseases. ABMC’s market cap is 591.61k, and its ROE is 9.99%. The company’s products are used by healthcare professionals, patients, and consumers worldwide.


    Investors in STANDARD BIOTOOLS have reason to be optimistic after the company reported strong second quarter earnings for FY2023. The positive results demonstrate the effectiveness of the company’s product and services and should further bolster investor confidence in the company’s long-term prospects. While further financial information is needed to make a more informed investment decision, the recently reported figures suggest that STANDARD BIOTOOLS is positioned for sustained success in the future.

    Recent Posts

    Leave a Comment